日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials

洛替拉纳滴眼液(0.25%)治疗蠕形螨睑缘炎的安全性和有效性:两项关键试验的汇总分析

Yeu, Elizabeth; Paauw, James D; Vollmer, Patrick; Berdy, Gregg J; Whitson, William E; Meyer, John; Simmons, Blake; Peterson, Jared D; Periman, Laura M; Boehmer, Blair E; Bloomenstein, Marc R; Whitley, Walter O; Koetting, Cecelia; Dhamdhere, Kavita; Neervannan, Sesha; Ciolino, Joseph B

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis

洛替拉纳滴眼液,0.25%,用于治疗蠕形螨睑缘炎

Davey, Pinakin Gunvant; Farid, Marjan; Karpecki, Paul; Gaddie, Ian Benjamin; Chan, Arthur; Mun, James; Neervannan, Sesha; Yeu, Elizabeth

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: "Drug Products, Including Biological Products, that Contain Nanomaterials"

美国药学科学家协会(AAPS)指导论坛关于FDA行业指导草案的报告:“含有纳米材料的药品,包括生物制品”

de Vlieger, Jon S B; Crommelin, Daan J A; Tyner, Katherine; Drummond, Daryl C; Jiang, Wenlei; McNeil, Scott E; Neervannan, Sesha; Crist, Rachael M; Shah, Vinod P